American Heart Association 2018 & Beyond

Early this month, the American Heart Association held its annual meeting. The AHA Scientific Sessions 2018 took place in Chicago, Illinois on November 10th through November 12th. What you will see below is a list of some of the key clinical trial presentations at the said event.

Cardiovascular Disease Prevention, Answers to Critical Questions

VITamin D and OmegA-3 Trial (VITAL)

“Nearly 10 years and more than $40 million dollars in the making, the VITAL trial has found no benefits to vitamin D or marine omega-3 fatty acid supplementation in the prevention of major cardiovascular disease events or cancer.”

Read the full article here.

REDUCE-IT

“A study in the current edition of the New England Journal of Medicine shows that a particular treatment significantly reduced cardiovascular events, including cardiovascular death, in patients who continue to have high triglyceride levels on statin therapy. These findings could lead to a more effective and life-saving treatment option when used with other combinations of drugs to treat cardiovascular disease.”

Read the full article here. Here’s an interview video of Deepak L. Bhatt, M.D. of Brigham and Women’s Hospital Heart and Vascular Center.

EWTOPIA 75

“Elderly patients treated with the cholesterol-absorption inhibitor ezetimibe had a significantly lower risk of atherosclerotic cardiovascular events over 5 years when compared with patients who received standard care . . .”

Read the full article here.

ODYSSEY Cost-Effectiveness Study

“If the PCSK9 inhibitor alirocumab (Praluent; Sanofi/Regeneron) is to be considered cost-effective by current willingness-to-pay standards, the drug needs to be priced at approximately $6,300 per year . . .”

Read the full article here.

american heart association

New Approaches to Cardiovascular Disease Prevention

DECLARE-TIMI 58

“AstraZeneca announced positive full results from the DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) for Farxiga (dapagliflozin) as a late-breaking abstract at the American Heart Association (AHA) Scientific Sessions . . .”

Read the full article here.

CIRT

“Low-dose methotrexate, a nonspecific anti-inflammatory agent used for the treatment of rheumatoid arthritis and other autoimmune disorders, failed to prevent cardiovascular events among patients with a prior MI or multivessel coronary artery disease, according to the results of a National Heart, Lung, and Blood Institute (NHLBI)-sponsored study.”

Read the full article here.

AKCEA

“Manufacturers of an investigational drug that targets lipoprotein(a) say they will move ahead with a pivotal trial following the promising results of a phase II dose-ranging study.”

Read the full article here.

Yoga-CaRe

“A yoga-based rehabilitation program following acute MI, called Yoga-CaRe, is as safe as a conventional program and feasible in an Indian population, according to new randomized data.”

Read the full article here.

american heart association

Use this Discount (ESNPWEEK15) when you enroll to our advanced American Heart Association courses:

ACLS, PALS, IV Therapy and Blood Withdrawal

Utilizing Technology in Improve Global Health Systems

BRIDGE CV Prevention

Results: Adherence to evidence-based therapies (antiplatelets, statins and ACE inhibitors) for high CV risk Brazilian patients was improved with the use of a multifaceted quality improvement educational intervention vs routine practice.

View the complete findings here.

BRIDGE Stroke

Results: The use of evidence-based therapies for patients admitted with acute ischemic stroke and transient ischemic attack did not significantly increase with the use of a multi-faceted quality improvement intervention.

View the complete findings here.

AF-ALERT

Alert-Based Computerized Decision Support to Increase Anticoagulation Prescription Prevents Stroke and Myocardial Infarction in High-Risk Hospitalized Patients with Atrial Fibrillation: A Randomized, Controlled Trial (AF-ALERT).

View the presentation here.

american heart association

Use this Discount (ESNPWEEK10) when you enroll to our basic American Heart Association courses:

Basic Life Support (BLS) & AHA Heartsaver® Workplace CPR

Acute Care Cardiology, Preserving the Brain and Heart

PRINCESS

“Transnasal evaporative cooling in out-of-hospital cardiac arrest is hemodynamically safe,” said Per Nordberg, MD, PhD, of Karolinska Institute in Stockholm, reporting for the Prehospital Resuscitation Intra-arrest Cooling Effectiveness Survival Study (PRINCESS). “I think this an important message, because guidelines state at the moment that you shouldn’t cool patients outside the hospital. We have shown that this is possible with this new method.”

Read the full article here.

Neuroprotect Post-CA Trial

“Using a transnasal evaporative cooling method for out-of-hospital cardiac arrest may be hemodynamically safe and shorten the time to target temperature, according to results of the PRINCESS trial . . .”

Read the full article here.

T-Time

“Low-dose coronary alteplase infused early after PCI does not reduce the likelihood of microvascular obstruction (MVO) in ST-segment elevation MI, the T-Time trial suggests.”

Read the full article here.

EARLY

“Sending patients with NSTE ACS not pretreated with a P2Y12 adenosine diphosphate (ADP)-receptor antagonist to the catheterization laboratory for invasive angiography within 2 hours of presentation reduced the risk of cardiovascular death or recurrent ischemia at 30 days when compared with a delayed strategy, a new study suggests.”

Read the full article here.

Door to Unload (DTU) Trial

Watch the video here as Navin Kapur, M.D., discusses the results of the FDA STEMI Door-to-Unloading (DTU) safety and feasibility randomized controlled trial, presented as a late-breaking study at the 2018 American Heart Association meeting.

Other Late-breaking Cardiology Trials Presented at AHA Scientific Sessions 2018

Beyond, what’s next? Or where and when next.

The American Heart Association Scientific Sessions 2019 and 2020 are set to take place in Philadelphia, Pennsylvania (November 16-18,2019) and Dallas, Texas (November 14-16, 2020), respectively.

 

 

 

This post originally appeared on Diagnostic and Interventional Cardiology. Click here to view the post in its entirety.